Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Menarini
Biotech
Menarini gets Georgiamune preclinical cancer drug in $1B deal
Maryland-based Georgiamune has licensed a preclinical cancer drug candidate to Stemline Therapeutics, which is owned by Italy's Menarini Group.
Michael Gibney
Oct 22, 2026 10:50am
Insilico Medicine, Menarini sign second $500M+ cancer drug deal
Jan 10, 2025 9:30am
Insilico nabs $500M+ biobucks deal for preclinical cancer asset
Jan 4, 2024 10:00am
Context cuts excess fat to carry biotech into ‘24
Sep 28, 2022 11:00am
As Sanofi's SERD falls, Menarini's advances with EU review
Aug 19, 2022 9:20am
Menarini, chased by 3 Big Pharmas, records breast cancer win
Oct 21, 2021 7:05am